BioWorld Science

Aug. 21, 2018

View Archived Issues

Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction

Read More

Polymorphisms in miRNA-146a and IRAK1 are associated with susceptibility to SLE and MS

Read More

Harbour BioMed licenses ex-China rights to Kelun-Biotech's A-167

Read More

Common pathway may underlie schizophrenia and PD

Read More

Getting at stored mRNAs part of fragile X problem

Read More

HDAC inhibitors optimized for CNS drug-like properties and hematological safety

Read More

Phase Ib data guide Novan's development of SB-414 for atopic dermatitis

Read More

New oral selective apelin agonist AM-2995 developed for heart disease treatment

Read More

Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798

Read More

Novo Nordisk reports topline PIONEER 5 results for oral semaglutide

Read More

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Read More

Biogen identifies new NRF2 activators

Read More

Adare Pharmaceuticals describes cysteamine prodrugs

Read More

Antiangiogenic compounds synthesized at Celgene

Read More

Vectura completes pediatric studies with VR-647 for asthma

Read More

Hanmi Science patents oncolytic compounds

Read More

New Rho kinase inhibitors described by Chiesi Farmaceutici

Read More

Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC

Read More

Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints

Read More

FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC

Read More

Ascentage Pharma opens phase I trial of APG-2575 in hematologic malignancies

Read More